Bridgebio Pharma Inc

Geschlossen

BrancheGesundheitswesen

77.96 1.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

76.01

Max

77.17

Schlüsselkennzahlen

By Trading Economics

Einkommen

24M

-167M

Verkäufe

40M

195M

EPS

-0.84

Gewinnspanne

-85.626

Angestellte

834

EBITDA

68M

-113M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+38.09% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

729M

14B

Vorheriger Eröffnungskurs

76.56

Vorheriger Schlusskurs

77.96

Nachrichtenstimmung

By Acuity

50%

50%

156 / 342 Ranking in Healthcare

Bridgebio Pharma Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Juli 2026, 23:41 UTC

News
Social Media

Meta shares rise in after-market trading as CEO Zuckerberg highlights upcoming AI benefits and announces new application Pocket, despite some setbacks.

2. Juli 2026, 23:32 UTC

News
Social Media

Microsoft launches AI initiative Microsoft Frontier Company with $2.5 billion backing. Shares are higher in after-market trading, continuing the broader software sector's upward trend.

2. Juli 2026, 23:31 UTC

News
Social Media
ETF Constituents
Correlated Moves

The Nasdaq 100 Index is higher in after-market hours, buoyed by U.S. jobless data and positive contributions from Microsoft, Meta, and Texas Instruments.

2. Juli 2026, 23:26 UTC

News

O'Reilly Automotive's $10 billion bid for Genuine Parts' division coincides with a decline in shares during after-market trading. Genuine Parts' shares rose significantly.

2. Juli 2026, 23:26 UTC

News

Qualcomm shares are higher in after-market hours despite Elon Musk's denial of a partnership with SpaceX and removal from Russell indexes.

2. Juli 2026, 23:16 UTC

Correlated Moves
News
Macro News
ETF Constituents

Vanguard Information Technology ETF gains after-hours, supported by positive contributions from Microsoft and Texas Instruments, following favorable U.S. jobless data.

2. Juli 2026, 23:16 UTC

News

Microchip Technology Inc shares are higher in after-market trading, despite concerns over AI-driven chip demand and a recent pullback in the Philadelphia Semiconductor Index.

2. Juli 2026, 23:12 UTC

News

Applied Materials shares advanced in after-hours trading, buoyed by positive equity market sentiment and gains in European indices like the DAX.

2. Juli 2026, 23:11 UTC

News
Macro Event
Correlated Moves

The USD/CZK exchange rate is lower today, reflecting recent U.S. labor market data and broader market sentiment influencing currency movements.

2. Juli 2026, 23:11 UTC

Macro Event
News

The USD/PLN exchange rate is lower today, reflecting a decline since Wednesday's close amid mixed U.S. labor market data and unusual volatility.

2. Juli 2026, 23:11 UTC

News
Social Media
Correlated Moves

The EUR/HKD exchange rate is rising, supported by U.S. Dollar weakness after disappointing nonfarm payroll data and positive GBP/USD movements.

2. Juli 2026, 23:11 UTC

News
Macro Event

The U.S. Dollar weakened against the Danish Krone following disappointing June nonfarm payroll data, which showed only 57,000 jobs added.

2. Juli 2026, 23:11 UTC

News
Social Media
Correlated Moves

Weakness in the U.S. Dollar, following disappointing payroll data, supports gains in GBP/HKD during Thursday's session. The asset is higher since Wednesday's close.

2. Juli 2026, 23:11 UTC

News
Macro Event
Correlated Moves

The USD/NOK exchange rate is lower, influenced by weaker U.S. job growth and correlated declines in USD/CAD. Volatility remains notable during Thursday's session.

2. Juli 2026, 23:11 UTC

Correlated Moves
News

Bitcoin remains higher despite SBI Crypto's cessation of mining operations. Earlier in the session, it pulled back from a peak amid significant volatility.

2. Juli 2026, 23:06 UTC

News

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

2. Juli 2026, 23:06 UTC

Correlated Moves
News

Gold trades slightly higher in after-market hours, supported by a modest rise in silver and tempered rate hike expectations following a weaker jobs report.

2. Juli 2026, 23:01 UTC

Macro Event
News

The USD/ZAR exchange rate is lower today, impacted by weaker U.S. Non-Farm Payrolls data revealing only 57,000 jobs added in June.

2. Juli 2026, 22:51 UTC

Macro Event
News

The Nikkei 225 Index declined in after-market hours, pressured by a sell-off in semiconductor shares and strengthened yen amid government intervention expectations.

2. Juli 2026, 20:13 UTC

ETF Constituents
News

Vanguard Large-Cap ETF declines after market close, influenced by broader market conditions and weaker U.S. jobs data. Holdings like Google and Johnson & Johnson also posted losses.

2. Juli 2026, 20:13 UTC

News
Correlated Moves

The Japanese yen strengthened to a two-week high against the U.S. dollar amid global uncertainties, while Invesco Currencyshares Japanese Yen Trust is trading roughly flat after hours.

2. Juli 2026, 20:07 UTC

Correlated Moves
News
Macro Event

The USD/HUF exchange rate is declining amid disappointing US job growth and a weaker US Dollar Index, with notable intraday volatility.

2. Juli 2026, 20:06 UTC

News

Liberty Global shares are higher as Liberty Latin America is added to several Russell Growth indices, potentially boosting visibility to passive funds and investors.

2. Juli 2026, 20:06 UTC

Correlated Moves
News
Macro Event

The USD/SGD exchange rate is lower today, reflecting pressure from weaker U.S. job growth data and a declining U.S. Dollar Index.

2. Juli 2026, 20:06 UTC

News
Correlated Moves

Gold prices are higher, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2. Juli 2026, 20:06 UTC

News
Correlated Moves

Gold prices rise amid weaker U.S. jobs data, which reported only 57,000 new jobs. Easing oil prices and rising silver also support gold's appeal.

2. Juli 2026, 20:06 UTC

News
Correlated Moves

Gold prices are higher today, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2. Juli 2026, 20:06 UTC

News
Correlated Moves

Gold prices are higher, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2. Juli 2026, 20:05 UTC

Correlated Moves
Social Media
ETF Constituents
News

The Communication Services Select Sector SPDR Fund is underperforming, reflecting a decline in the Communications sector. The fund remains roughly flat since Wednesday's close.

2. Juli 2026, 20:05 UTC

News
Social Media

Tesla Inc's stock is declining amid profit-taking despite strong delivery figures. Analysts raised the price target to $430, but investor concerns persist.

Peer-Vergleich

Kursveränderung

Bridgebio Pharma Inc Prognose

Kursziel

By TipRanks

38.09% Vorteil

12-Monats-Prognose

Durchschnitt 106.59 USD  38.09%

Hoch 157 USD

Tief 82 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bridgebio Pharma Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

18 ratings

17

Buy

1

Halten

0

Sell

Stimmung

By Acuity

156 / 342 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat